Longterm beneficial effect of canakinumab in colchicine-resistant familial mediterranean fever
Ημερομηνία
2017Γλώσσα
en
Λέξη-κλειδί
Επιτομή
Objective. To assess the efficacy and safety of the interleukin-1β (IL-1β) inhibitor canakinumab in all adolescent and adult patients with familial Mediterranean fever (FMF) identified from the Greek National Registry for off-label drug use between 2010 and 2015. Methods. In this retrospective longitudinal outcome study, clinical and laboratory data were collected from 14 patients (7 men) aged median 38.5 years (range 13-70), with median disease duration of 14 years, and active FMF despite colchicine (n = 9) or both colchicine and anakinra (n = 5). Results.All patients continued to receive canakinumab at last visit (median of 18 mos, range 13-53), which was initially given as monotherapy (n = 8) or in combination with colchicine and/or corticosteroids, every 4 (n = 7), 6 (n = 2), or 8 weeks (n = 5). Eleven patients (79%), including 6 receiving monotherapy, achieved complete clinical remission within 2 months (median), while normalization of all laboratory variables denoting inflammation occurred in 92% at 3 months (median). The remaining 3 patients achieved partial responses. Responses were sustained in all but 4 patients, who relapsed. Reducing the canakinumab administration interval from 8 or 6 weeks to 4 weeks led to suppression of disease activity in the relapsing patients. On the other hand, drug administration interval could be safely increased in 2 patients in remission. Corticosteroid doses were significantly reduced during followup. Canakinumab was well tolerated; 1 patient experienced a urinary tract infection and another one a viral gastroenteritis. Conclusion. Treatment with canakinumab in an individualized dosing scheme results in rapid and sustained remission in colchicine-resistant FMF. © 2016 Journal of Rheumatology.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Clinical features and outcomes of patients with tubercular uveitis treated with antitubercular therapy in the collaborative ocular tuberculosis study (COTS)-1
Agrawal R., Gunasekeran D.V., Grant R., Agarwal A., Kon O.M., Nguyen Q.D., Pavesio C., Gupta V., Gupta B., Aggarwal K., Murthy S.L., Westcott M., Phaik C.S., McCluskey P., Ling H.S., Teoh S., Cimino L., Biswas J., Narain S., Agarwal M., Mahendradas P., Khairallah M., Jones N., Tugal-Tutkun I., Babu K., Basu S., Carreño E., Lee R., Al-Dhibi H., Bodaghi B., Invernizzi A., Goldstein D.A., Herbort C.P., Barisani T., González-López J.J., Androudi S., Bansal R., Moharana B., Mahajan S., Esposti S., Tasiopoulou A., Nadarajah S., Agarwal M., Abraham S., Vala R., Singh R., Sharma A., Sharma K., Zierhut M., Raje D., Cunningham E., Kempen J., Collaborative Ocular Tuberculosis Study (COTS)-1 Study Group (2017)IMPORTANCE Eradication of systemic tuberculosis (TB) has been limited by neglected populations and the HIV pandemic. Whereas ocular TB often presents as uveitis without any prior evidence of systemic TB, the existing ... -
The effect of 5-azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes
Diamantopoulos P.T., Symeonidis A., Pappa V., Kotsianidis I., Galanopoulos A., Pontikoglou C., Anagnostopoulos A., Vassilopoulos G., Zikos P., Hatzimichael E., Papaioannou M., Megalakaki A., Repousis P., Kotsopoulou M., Dimou M., Solomou E., Dryllis G., Tsokanas D., Papoutselis M.-K., Papageorgiou S., Kyrtshonis M.-C., Kourakli A., Papadaki H., Panayiotidis P., Viniou N.-A. (2021)The regimen of 5-azacytidine for patients with myelodysplastic syndrome (MDS) has remained unchanged since its first approval. Although several modifications have since been made and delays and dose reductions are common ... -
Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias
Bawazeer G.A., Alkofide H.A., Alsharafi A.A., Babakr N.O., Altorkistani A.M., Kashour T.S., Miligkos M., AlFaleh K.M., Al-Ansary L.A. (2021)Background: The management of anticoagulation therapy around the time of catheter ablation (CA) procedure for adults with arrhythmia is critical and yet is variable in clinical practice. The ideal approach for safe and ...